We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Commentary: Reconsidering Pharmaceutical Research and Development Investments.
- Authors
GAGNON, MARC-ANDRÉ
- Abstract
Following Lee and colleagues' (2023) article explaining how Canadians are being shortchanged by drug companies when it comes to investments in research and development (R&D), this rejoinder adds context and appends two other very problematic elements in the debate between wishful narratives over the industry's contribution in R&D and actual numbers. First, even the current stricter definition of R&D investment might simply be too large considering that elements such as seeding trials -- a well-known marketing device -- can be accounted for as R&D expenditures. Second, this rejoinder identifies how Statistics Canada acted in concert with Innovative Medicines Canada to reinforce the industry's preferred narratives around R&D expenditures. This situation puts into question the trustworthiness of Canada's statistical agency.
- Subjects
CANADA; MEDICAL research &; economics; PHARMACEUTICAL industry &; economics; INVESTMENTS; MARKETING
- Publication
Healthcare Policy, 2023, Vol 18, Issue 3, p25
- ISSN
1715-6572
- Publication type
Article
- DOI
10.12927/hcpol.2023.27037